Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. (QUIT) Stock Analysis

$6.060

-0.249 (-4.11%)At close

Loading chart…
High
6.330
Open
6.160
VWAP
6.14
Volume
822.53K
Mkt Cap
—
Low
6.037
Amount
5.05M
EV/EBITDA, TTM
0.00

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

AI analysis of Achieve Life Sciences, Inc. (QUIT)

Buy

BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.

Valuation Metrics

The current forward P/E ratio for Achieve Life Sciences, Inc. (QUIT) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E
Current P/E
0.00

Forward EV/EBITDA

5Y Average EV/EBITDA
Current EV/EBITDA
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
20.19
Current P/S
20.19
Overvalued
20.19
Undervalued
20.19

Whales holding QUIT

T

TPG Capital, L.P.

+ HoldingQUIT

+27.03%

3M Return

L

Logos Global Management, L.P.

+ HoldingQUIT

+24.07%

3M Return

P

Paradigm Biocapital Advisors LP

+ HoldingQUIT

+19.24%

3M Return

F

Frazier Life Sciences Management, LP

+ HoldingQUIT

+10.54%

3M Return

V

VR Management, LLC

+ HoldingQUIT

+9.81%

3M Return

QUIT FAQ — answered by Alphio AI

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading